Depomed (DEPO) Tops Q3 EPS by 3c, Revenue Comes in Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Depomed Announces Third Quarter 2017 Financial Results
November 7, 2017 4:07 PM EST- Third Quarter Net Sales of $95 Million-
- Slán Medicinal Holdings Transaction Creates New Specialty Unit and Diversifies Business -
- Updates Full-Year Guidance -
- Conference Call Scheduled for Today at 4:30 PM EST; Dial In Information Below -
NEWARK, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq: DEPO) today reported financial results for the quarter ended September 30, 2017 and provided an update to the business.
During the third quarter, we made... More
